Clinical Trial Update, Recommendations for Approval, Share Repurchase Programs, and Closing of Public Offering - Analyst Notes on Medtronic, Regeneron, Lilly, United Therapeutics and Receptos
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, July 2, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Medtronic, Inc. (NYSE: MDT), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Eli Lilly and Company (NYSE: LLY), United Therapeutics Corporation (NASDAQ: UTHR) and Receptos Inc. (NASDAQ: RCPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4341-100free.
--
Medtronic, Inc. Analyst Notes
On June 25, 2014, Medtronic, Inc. (Medtronic) announced that the results from a clinical trial, published in The New England Journal of Medicine, showed that continuous cardiac monitoring with its Reveal® XT Insertable Cardiac Monitor (ICM) detects atrial fibrillation (AF) in stroke patients with undetermined causes (cryptogenic stroke), better as compared to standard care. According to the Company, the clinical trial, called the Cryptogenic Stroke And Underlying Atrial Fibrillation (CRYSTAL AF), is a global study that met its primary endpoint by demonstrating that continuous monitoring with the Reveal ICM detects AF in 6.4 times more patients as compared to standard care at six months (p=0.0006), 7.3 times more patients at 12 months (p<0.0001), and 8.8 times more patients at 36 months (p<0.0001). The Company added that when followed for 36 months, 30% of ICM patients had AF detected. The full analyst notes on Medtronic are available to download free of charge at:
http://www.analystsreview.com/Jul-02-2014/MDT/report.pdf
--
Regeneron Pharmaceuticals Inc. Analyst Notes
On June 27, 2014, Regeneron Pharmaceuticals Inc. (Regeneron) announced that European Committee for Medicinal Products for Human Use (CHMP) has recommended EYLEA® (aflibercept) Injection for approval for the treatment of visual impairment due to diabetic macular edema (DME). George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer, Regeneron, and President, Regeneron Laboratories said, "Diabetes is a growing health concern worldwide and this milestone brings us one step closer to being able to offer patients and physicians in the European Union a new therapeutic option for the treatment of diabetic macular edema." The Company further stated that the European Commission's decision is expected in H2 2014. The full analyst notes on Regeneron are available to download free of charge at:
http://www.analystsreview.com/Jul-02-2014/REGN/report.pdf
--
Eli Lilly and Company Analyst Notes
On June 25, 2014, Eli Lilly and Company (Lilly) announced that Lilly Diabetes has helped fund a scholarship program of The Diabetes Scholars Foundation for a third consecutive year. According to the Company, the Foundation gives out college scholarships to a gifted group of young adults who along with successfully managing their diabetes have also excelled in the classroom and in the community, proving that diabetes is not a hindrance to pursue one's goals. Lilly stated that since its inception in 2012, the Lilly Diabetes Tomorrow's Leaders Scholarship program has funded over 60 scholarships, while in 2013 it donated $200,000 to support scholarships through 2015. For 2014, Lilly Diabetes Scholarships will award additional 21 high school graduates to assist them in attending universities throughout the U.S. The full analyst notes on Lilly are available to download free of charge at:
http://www.analystsreview.com/Jul-02-2014/LLY/report.pdf
--
United Therapeutics Corporation Analyst Notes
On June 27, 2014, United Therapeutics Corporation (United Therapeutics) announced that its Board of Directors has authorized the repurchase of up to an additional $500 million of the Company's common stock, with effect from August 1, 2014, which will remain open for up to a year. United Therapeutics also announced the recent completion of its previously announced repurchase program by purchasing approximately 4.6 million shares of its common stock. The full analyst notes on United Therapeutics are available to download free of charge at:
http://www.analystsreview.com/Jul-02-2014/UTHR/report.pdf
--
Receptos Inc. Analyst Notes
On June 24, 2014, Receptos Inc. (Receptos) announced the closing of the previously announced underwritten public offering of 4,433,000 shares at a price to the public of $40.25 per share of the Company's common stock. According to the Company, before the deduction of underwriting discounts and commissions and other estimated offering expenses, the gross proceeds from this offering were approximately $178.4 million. Receptos added that it has granted a 30-day option to the underwriters to purchase up to an additional 664,950 shares of common stock. The Company stated that the net proceeds from this offering will be used to fund the continued development of its product candidate RPC1063 in ongoing clinical trials for relapsing multiple sclerosis and ulcerative colitis, the development of its in-licensed product candidate RPC4046 in a clinical trial for eosinophilic esophagitis, and other ongoing preclinical and research programs as well as for general corporate purposes which include working capital. The full analyst notes on Receptos are available to download free of charge at:
http://www.analystsreview.com/Jul-02-2014/RCPT/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article